ORIGINAL RESEARCH
Published on 10 Dec 2024
Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab
doi 10.3389/fimmu.2024.1506355
- 577 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Advancements in Antibody-Based Immunotherapy and Cancer Vaccines for Hepatocellular Carcinoma
Advancements in Antibody-Based Immunotherapy and Cancer Vaccines for Hepatocellular Carcinoma
2,198
Total downloads
6,860
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 23 Oct 2024
Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
doi 10.3389/fimmu.2024.1491857
- 1,119 views
SYSTEMATIC REVIEW
Published on 02 Aug 2024
Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis
doi 10.3389/fimmu.2024.1421520
- 1,219 views
- 1 citation
ORIGINAL RESEARCH
Published on 26 Jul 2024
TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study
doi 10.3389/fimmu.2024.1430571
- 1,223 views
- 1 citation
Published in
Frontiers in Immunology
- Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted:
Impact
- 6,860Topic views
- 3,494Article views
- 2,198Article downloads